Posts in category: Uncategorized

Data from a national clinical trial shows that a striking 89% of patients with desmoplastic melanoma responded to immunotherapy (pembrolizumab) alone, suggesting that many patients could avoid the risk for toxicity from combination therapies and achieve cancer control with this approach to treatment.

The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with NF2 mutations, according to results of a Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center. The first-in-human study was presented today at the American Association for Cancer Research (AACR) Annual Meeting 2023.

A new study of worldwide polling data suggests that a person’s income rank relative to their peers is linked to their experience of physical pain, with a lower income rank linked to a higher likelihood of experiencing pain. It is the first time such a relationship has been shown.

Despite recent advances, ovarian cancer remains the fifth leading cause of cancer-related deaths among women, and there’s a critical need for new treatment options, especially for advanced cancers that grow back after standard of care treatment. Results from a preclinical study, led by researchers from the Perelman School of Medicine at the University of Pennsylvania, verified a new target for drug-resistant ovarian cancer and provided data to support a treatment approach that is already making its way into clinical trials.

For many teens, that first formal job as a fast-food cashier, barista or lifeguard is a rite of passage.

An international consensus statement on the safest and most effective way to implant a pacing system that mimics the heart’s normal function is published today in EP Europace, a journal of the European Society of Cardiology (ESC). The document is being launched at the EHRA Conduction System Pacing (CSP) Summit and will be discussed during EHRA 2023, a scientific congress of the ESC.

Antibiotics help to fight bacterial infections, but they can also harm the helpful microbes living in the gut, which can have long-lasting health consequences.

During the 2022-2023 winter season Denmark experienced a surge in infections caused by group A streptococci (GAS), including the more dangerous, invasive types of infections (iGAS). Incidence of iGAS is highest among the elderly, but the largest relative increase from previous seasons was seen among children. The study is being presented to the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2023, Copenhagen, 15-18 April), by Thor Bech Johannesen and Steen Hoffmann, Statens Serum Institut, Copenhagen, Denmark, and colleagues.

New research from France shows that infections cause by Group A Streptococcus (GAS) fell by 80% as the first COVID lockdown took effect in March 2020 and stayed at low levels until March 2022, from which point they increased by 18% a month to rise well above pre-COVID levels.